Aeris Capital, AG, is a Zurich, Switzerland based private equity fund and financial advisor. Aeris Capital invests globally in all asset classes with a long-term approach focused on achieving risk adjusted returns.
In February 2017, Aeris Capital rebranded to Calibrium AG.
Aeris Capital has made investments in Sonetik, Smaato, Affimed Therapeutics, Jiff, Butterfly Network, Curetis, Solstice Biologics, GenomeDx, Glam Media and Decipher Biosciences.
They have exited their investments in Smaato, ConforMIS, Jiff, Curetis, Crescendo Bioscience, Livescribe, Affimed Therapeutics, Invincea, Mode Media and SynapSense.